IL10 and irritable bowel syndrome: SCFAs, in general, are also capable of reprogramming the metabolic activity of immune cells, leading to the induction of regulatory B cells (Breg) and enhancing IL-10 (a pleiotropic cytokine) production and suppressing Th17 cells, which are important processes in controlling the inflammatory bowel diseases (IBD) and autoimmune disorders [45].